Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
71
resultados
Última actualización
26/04/2026 [06:45:00]
Resultados 50 a 71 de 71
Resumen de: AU2025316407A1
The present disclosure is directed to methods of treating, for example, newly diagnosed multiple myeloma.
Resumen de: WO2026074086A1
The present invention relates to cells expressing chimeric antigen receptors against BCMA and a glutamine transporter, and uses thereof in the treatment of cancer or autoimmune diseases. The invention also relates to a method for the prognosis of multiple myeloma in a subject.
Resumen de: WO2026076264A1
Provided here are methods of treating lymphomas for example, peripheral T-cell lymphomas (PTCLs) (e.g., nodal Tfh cell lymphomas) and/or cutaneous T-cell lymphomas (CTCLs) in a subject, by administering to the subject Compound A, or a pharmaceutically acceptable salt thereof. In some cases, the lymphomas are BCL6 positive. In some cases, the lymphomas are relapsed or refractory. In some cases, the subjects are treatment-naïve (i.e., previously untreated).
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP4722388A1
The invention relates to a method of predicting an outcome of a subject having AML, the method comprising determining or receiving the result of a determination of six or more gene expression levels selected from a gene signature, and, optionally, providing the prediction to a medical caregiver or the subject. The invention further describes an apparatus and a computer program product configured to prediction outcome of a subject having AML. In addition the invention described the use of a kit in prediction outcome of a subject having AML, and describes a therapy for use in the treatment of AML, the use comprising predicting an outcome of a subject having AML and providing a therapy adapted to the outcome.
Resumen de: EP4721737A1
Use of a pharmaceutical composition comprising a new compound comprising diazanylidenesulfonyl structure in the preparation of a medicament for treating anemia-related disease. The anemia-related disease can involve myelodysplastic syndrome (MDS), hemoglobinopathy, sickle cell anemia (SCD), β-thalassemia, hereditary non-spherocytic hemolytic anemia, hemolytic anemia, hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia, paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia, congenital anemia or anemia of chronic disease.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP4721734A1
0001 The use of mitoxantrone liposome combined with cytarabine, or further combined with other drugs, such as homoharringtonine or venetoclax, in the preparation of drugs used for treating acute myeloid leukemia (AML). Provided is a method of treating AML, the method comprising administering to an AML patient a pharmaceutical composition comprising mitoxantrone liposome and cytarabine, wherein the pharmaceutical composition may also comprise homoharringtonine or venetoclax.
Resumen de: US20260092085A1
A novel peptide nucleic acid (PNA) oligomer capable of forming a PNA/RNA/PNA triplex when binding to its target RNA is described. An anti-micro RNA (miRNA) capable of binding miR-155 was designed based on the novel PNA oligomer and was shown to significantly decrease miR-155 expression in vitro in lymphoma cell lines. In vivo testing in xenograft mouse models resulted in reduced miR-155 expression followed by reduced tumor growth. Methods of making and using the novel PNA oligomer for targeting other coding and noncoding RNAs are described.
Resumen de: WO2026067824A1
The present invention belongs to the technical field of stem cells. Provided are a culture medium for induced hypoblast stem cells and the use thereof. Provided is a culture medium for induced hypoblast stem cells. The components of the culture medium comprise platelet-derived growth factor AA, a leukemia inhibitory factor, fibroblast growth factor 4, GSK-3α/β inhibitor CHIR99021, TGF-β type I receptor inhibitor A83-01, and bone morphogenetic protein 4. The culture medium for induced hypoblast stem cells can accurately regulate the activity of key signaling pathways such as NODAL, BMP, WNT, FGF, and JAK/STAT in the process of somatic cell reprogramming, and ensure that the properties of hypoblast stem cells are maintained in the process of somatic cell reprogramming to support the self-renewal and hypoblast lineage induction of somatic cells in the reprogramming process, thereby realizing the fate transition of somatic cells to hypoblast stem cells.
Resumen de: AU2024390850A1
Methods of treating multiple myeloma by administering a bispecific antibody that binds to CD3 and BCMA to a patient in need are provided.
Resumen de: WO2026068605A1
The present disclosure provides methods of predicting whether a subject is at risk of developing resistance to a treatment for chronic myelogenous leukaemia (CML) and/or progressing to blast crisis phase, wherein the subject has CML or has been diagnosed with CML. The present disclosure also provides methods of selecting a subject for treatment with a given therapy, wherein the subject has chronic myelogenous leukaemia (CML) or has been diagnosed with CML. The present disclosure also provides kits useful for performing said methods.
Resumen de: WO2026069350A2
An Umbilical cord derived mesenchymal stem cell (UC-MSC) conditioned media (UC- MSC-CM) composition of the range from 5%-100% possessing immunomodulatory effect inhibiting tumour growth when administered intraperitoneally and intravenously. MSC- CM arrests cell cycle in leukaemia cells (K-562 and HL-60), lung cancer cells (A549 and HOP-62), breast cancer cells (MDA-MB-231 and MCF-7) and cervical cancer cells (HeLa). Elevated levels of IL-6, TIM3 and TIMP2 in MSC-CM confer to its immunomodulatory function by leading to an increase in expression of activation markers, cytotoxic granules, mucosal associated invariant T cells and decreasing the inflammasome pathway activation, consequently decreasing the levels of innate immune inflammasome pathway molecules in treated xenograft tumor tissues. MSC-CM as an adjunct with IL-12 augments cytotoxic potential against cancer cell lines. Tumor inhibition effect of MSC-CM is shown by significant reduction of relative tumor volume which is expressed by fold change of genes involved in various pathways affecting xenograft tumor growth.
Resumen de: WO2026072990A1
The present disclosure relates to methods of treating T-cell large granular lymphocytic leukemia (T-LGLL) with antibodies, or antigen-binding fragments thereof, that specifically bind to killer cell lectin-like receptor G1 (KLRG1), and methods for maintaining remission of T-cell large granular lymphocytic leukemia in a patient.
Resumen de: WO2026072888A1
Cell surface polypeptides SEMA-4A and FCRL3 have been identified as being associated with multiple myeloma. Accordingly, these peptides represent targets for immuno-based therapeutic strategies for treating multiple myeloma. Antibodies that specifically binds to one of these polypeptides can be used to treat multiple myeloma. Accordingly, new compositions and methods utilizing novel antibodies that target SEMA-4A and FCRL3 are described.
Resumen de: WO2026072967A1
The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: AU2024341370A1
The present disclosure provides SOS-1 inhibitors, such as bicyclic compounds or macrocyclic compounds, alone or in combination with TKI - resitant to BCR-ABL tyrosine kinase, such as dasatinib or imatinib, for use in the treatment of philadelphia chromosome positive (Ph+) blood cancer, such as CML (chronic myelogenous leukemia, also named chronic myeloid leukemia), Ph+ALL (acute lymphoblastic leukemia) and Ph+AML (acute lymphoblastic lymphoma).
Resumen de: US20260092097A1
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
Resumen de: AU2024360739A1
The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.
Resumen de: NZ774030A
The present invention relates to isolated anti-human CD45RC antibodies or binding fragments thereof, to nucleic acids and expression vector encoding the same, to compositions comprising the same, and to uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).
Nº publicación: NZ802272A 27/03/2026
Solicitante:
GERON CORP
Resumen de: NZ802272A
This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and/or have MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA).
BOPI
Sede Electrónica
